On Wednesday, data from that drug are being presented at the San Antonio Breast ... Early-stage biotech companies are almost always raising money.
News
- Experimental Drugs Achieve Unusually Good Results Against Hard-To-Treat Advanced Breast ...
- Puma Bio up 5% premarket on Nerlynx data in heavily pretreated breast cancer patients
Puma Biotechnology (NASDAQ:PBYI) is up 5% premarket on light volume in response to results from an ongoing open-label Phase 2 basket study, SUMMIT, ... The data were presented at the San Antonio Breast Cancer Symposium.
- Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in ...
The results were presented at the San Antonio Breast Cancer Symposium (SABCS) in San .... INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY.
- SABCS: 10-year study shows targeted radiation can be as effective as whole-breast doses against ...
A 10-year clinical trial of over 4,200 patients presented at the annual San Antonio symposium last year also found that it was unable to reject the idea ...
- Silverback Therapeutics Announces Preclinical Data at 2019 San Antonio Breast Cancer ...
Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, announced the ...